Showing posts with label Asia Cholesterin Industry Analysis. Show all posts
Showing posts with label Asia Cholesterin Industry Analysis. Show all posts

Tuesday, July 31, 2018

Evolution in Clinical Studies to Drive Asia Cholesterin Industry: Ken Research

Cholesterin is a German word for cholesterol which is a crystalline, fatty natural substance found in almost all animal cells. Apart from bile, cholesterol is produced in liver, brain, nerves and blood in all animals. It plays a major role in cell membrane stabilization and nerve function, production of sex hormones and other processes within the body. It is a component of the cell membrane that helps in increasing stability of the membrane when coupled with proteins. It also helps to introduce signalling substance into and out of the cell membrane. Every human body contains about 140g of cholesterol additional to the 95% of cholesterol within the cells and cell membranes. Lipoproteins help in supplying the cells with cholesterol which vary in densities according to their behaviour during various functions. Cholesterol is a polycyclic alcohol and it is not fat. It is a sensitive oxidant and autoxidation process leads to many reactions within a human body.

In the cholesterol synthesis process, PCSK9 is the chief component. Investigational antibodies promise to block the enzyme and subsequently lower LDL cholesterol. Cholesterylester transfer protein (CETP) increases HDL cholesterol in order to reduce the risk of cardiovascular disease. This advanced treatment is appealing due to its success and mechanisms of action. It needs to be proven that lowering LDL cholesterol levels is beneficial to the biological system. Drug makers or manufacturers are also hesitant to cholesterylester transfer protein (CETP), inhibitors after Pfizer's torcetrapib and Roche's dalcetrapib both failed in trials during the development of advanced cholesterol drugs. Majority of the drug companies encouraged the development of HDL-boosters that could be an heir to best-selling LDL cholesterol lowering medicines.

According to the study “Asia Cholesterin Industry Situation and Prospects Research report”, Asian cholesterin industry is spread across China, India, Korea, Japan, Saudi Arabia and other regions. All the leading vendors are increasingly focusing on developing new drugs that exhibit long-term reliability. The vendors are increasingly competing against each other based on factors such as price, features, and product quality. The leading players in Asian cholesterin industry are Dishman, NK, Nippon Fine Chemical, Zhejiang Garden Biochemical, Jingkang Biotechnology and Tianqi Chemical. Cholesterin is used in cosmetic, pharmaceutical and others industries for various applications. Lanolin source and animal brain source are the two types of cholesterin available in Asian markets.

Asia accounts for a largest share in the cholesterin market due to health awareness, enhanced standard of living, demand for quality cosmetics products and advanced pharmaceuticals. The increasing consumption of cholesterin products for various applications is encouraging the market towards expansion attracting huge recognition and the trend will continue over the next few years in Asian markets.

To know more, click on the link below:

Contact Us:
Ken Research 
Ankur Gupta, Head Marketing & Communications
+91-9015378249